US4451477A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bendazac treatment of cataract
Assignee: Angelini Acraf SpA
•
Filing: 1982-06-08
•
Granted: 1984-05-29
•
Expires: 2002-06-08
Abstract
Abstract It was discovered that bendazac, or [(1-benzyl-1H-indazol-3-yl)oxy] acetic acid, when administered in a form suitable to obtain therapeutic tissue concentrations, determines a regression of cataract. It was demonstrated in particular, that the lysine salt of bendazac is well adapted for this use since it produces adequate tissue concentrations following both oral administration and topical application on the eye. The chemical and physical characteristics of this bendazac salt are described here together with the preparation techniques.
Inventors
- 👤 Bruno Silvestrini
- 👤 Leandro Baiocchi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:45
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61P; A61P27/00; A61P27/02; A61P27/12
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
21 words
A method for the treatment of cataracts in a human comprising administering to said human a therapeutically effective amount of bendazac.
Claim 2
Independent Claim
21 words
A method for the treatment of cataracts in a human comprising administering to said human a therapeutically effective amount of bendazac.
Claim 3
Dependent Claim
17 words
A method for the treatment of cataracts according to claim 1, wherein said bendazac is administered orally.
Claim 4
Dependent Claim
50 words
A method for the treatment of cataracts according to claim 2, wherein said bendazac is administered in a quantity sufficient to achieve an effective blood level of 20-40 μg/ml in the range of 455 to 1824 mg per day in an acceptable pharmaceutical form suitable to obtain effective tissue concentrations.
Claim 5
Dependent Claim
23 words
A method for the treatment of cataracts according to claim 3, wherein said bendazac is administered in the form of a lysine salt.
Claim 6
Dependent Claim
28 words
A method for the treatment of cataracts according to claim 4, wherein said bendazac lysine salt is administered at a dosage of 750 to 3000 mg per day.
Claim 7
Dependent Claim
26 words
A method for the treatment of cataracts according to claim 5, wherein said bendazac lysine salt is administered subdivided in 2 or more doses per day.
Claim 8
Dependent Claim
21 words
A method for the treatment of cataracts according to claim 1, wherein said bendazac is administered directly to the affected eye.
Claim 9
Dependent Claim
32 words
A method for the treatment of cataracts according to claim 7, wherein said bendazac is administered in the form of an acceptable pharmaceutical carrier in concentration in the range of 0.1-1 percent.
Claim 10
Dependent Claim
32 words
A method for the treatment of cataracts according to claim 8, in which said bendazac is administered 2 to 3 times a day, in the quantity of 3 drops for each application.
Claim 11
Dependent Claim
23 words
A method for the treatment of cataracts according to claim 7, in which bendazac is administered in the form of a lysine salt.
Claim 12
Dependent Claim
22 words
A method for treatment of cataracts according to claim 1 wherein said bendazac is in the form of a pharmaceutically acceptable salt.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-29 | 1987-11-28 | 1988-05-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-29 | 1991-11-28 | 1992-05-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-29 | 1995-11-28 | 1996-05-29 | $7700.00 | Window Closed / Lapsed |